Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $415.8 million.

  • Tg Therapeutics' Total Non-Current Liabilities rose 641.36% to $415.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $415.8 million, marking a year-over-year increase of 641.36%. This contributed to the annual value of $351.5 million for FY2024, which is 10834.48% up from last year.
  • Per Tg Therapeutics' latest filing, its Total Non-Current Liabilities stood at $415.8 million for Q3 2025, which was up 641.36% from $424.0 million recorded in Q2 2025.
  • Tg Therapeutics' Total Non-Current Liabilities' 5-year high stood at $424.0 million during Q2 2025, with a 5-year trough of $97.5 million in Q3 2021.
  • In the last 5 years, Tg Therapeutics' Total Non-Current Liabilities had a median value of $210.4 million in 2024 and averaged $244.1 million.
  • As far as peak fluctuations go, Tg Therapeutics' Total Non-Current Liabilities tumbled by 518.87% in 2022, and later soared by 10834.48% in 2024.
  • Tg Therapeutics' Total Non-Current Liabilities (Quarter) stood at $142.1 million in 2021, then fell by 5.19% to $134.7 million in 2022, then rose by 25.22% to $168.7 million in 2023, then skyrocketed by 108.34% to $351.5 million in 2024, then grew by 18.29% to $415.8 million in 2025.
  • Its Total Non-Current Liabilities was $415.8 million in Q3 2025, compared to $424.0 million in Q2 2025 and $417.2 million in Q1 2025.